Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 12, Issue 3, 2016, Pages 655-664

  Kim, Myung Soo ^a,b   Haney, Matthew J ^a,b   Zhao, Yuling ^a,b   Mahajan, Vivek ^a,b   Deygen, Irina ^c   Klyachko, Natalia L ^a,b,c   Inskoe, Eli ^b   Piroyan, Aleksandr ^a,b   Sokolsky, Marina ^a,b   Okolie, Onyi ^b   Hingtgen, Shawn D ^a,b   Kabanov, Alexander V ^a,b,c   Batrakova, Elena V ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

Cancer; Drug resistance; Exosome; Paclitaxel; Pgp

Indexed keywords

CELLS; DRUG PRODUCTS; DRUG THERAPY;

CANCER; CHEMOTHERAPEUTIC AGENTS; DRUG DELIVERY VEHICLES; DRUG RESISTANCE; EXOSOME; LEWIS LUNG CARCINOMATA; PACLITAXEL; SUSTAINED DRUG RELEASE;

DISEASES;

ALIX PROTEIN; BETA ACTIN; FLOTILLIN; MEMBRANE PROTEIN; PACLITAXEL; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL LINE RAW 264.7; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; EXOSOME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LEWIS CARCINOMA; LUNG METASTASIS; MACROPHAGE; MICELLE; MOUSE; MULTIDRUG RESISTANCE; NANOENCAPSULATION; NONHUMAN; SIZE EXCLUSION CHROMATOGRAPHY; SUSTAINED DRUG RELEASE; TUMOR GROWTH; ANIMAL; C57BL MOUSE; CELL LINE; CHEMISTRY; DOG; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; LUNG; LUNG NEOPLASMS; PATHOLOGY; SECONDARY; TUMOR CELL LINE; ULTRASOUND;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE; CELL LINE, TUMOR; DOGS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EXOSOMES; FEMALE; LUNG; LUNG NEOPLASMS; MACROPHAGES; MICE; MICE, INBRED C57BL; PACLITAXEL; SONICATION;

EID: 84959440540     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.10.012     Document Type: Article

References (47)

1. Gharpure K.M., Wu S.Y., Li C., Lopez-Berestein G., Sood A.K. Nanotechnology: future of oncotherapy. Clin Cancer Res 2015, 21(14):3121-3130. [Epub 2015/07/17].
2. Abu Lila A.S., Kiwada H., Ishida T. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release 2013, 172(1):38-47. [Epub 2013/08/13].
3. Hayeshi R., Masimirembwa C., Mukanganyama S., Ungell A.L. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci 2006, 29(1):70-81. [Epub 2006/07/19].
4. Bauer K.S., Karp J.E., Garimella T.S., Wu S., Tan M., Ross D.D. A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia. Leuk Res 2005, 29(3):263-271. [Epub 2005/01/22].
5. Simpson R.J., Jensen S.S., Lim J.W. Proteomic profiling of exosomes: current perspectives. Proteomics 2008, 8(19):4083-4099. [Epub 2008/09/10].
6. Kalani A., Tyagi A., Tyagi N. Exosomes: mediators of neurodegeneration, neuroprotection and therapeutics. Mol Neurobiol 2014, 49(1):590-600. [Epub 2013/09/04].
7. Dong X., Mumper R.J. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 2010, 5(4):597-615. [Epub 2010/06/10].
8. Yang X., Yi C., Luo N., Gong C. Nanomedicine to overcome cancer multidrug resistance. Curr Drug Metab 2014, 15(6):632-649. [Epub 2014/09/27].
9. Markman J.L., Rekechenetskiy A., Holler E., Ljubimova J.Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 2013, 65(13-14):1866-1879. [Epub 2013/10/15].
10. Koziara J.M., Whisman T.R., Tseng M.T., Mumper R.J. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J Control Release 2006, 112(3):312-319. [Epub 2006/04/22].
11. Ratajczak J., Wysoczynski M., Hayek F., Janowska-Wieczorek A., Ratajczak M.Z. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006, 20(9):1487-1495. [Epub 2006/06/23].
12. Kalani A., Kamat P.K., Chaturvedi P., Tyagi S.C., Tyagi N. Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. Life Sci 2014, 107(1-2):1-7. [Epub 2014/05/02].
13. Mathivanan S., Ji H., Simpson R.J. Exosomes: extracellular organelles important in intercellular communication. J Proteome 2010, 73(10):1907-1920. [Epub 2010/07/06].
14. Alvarez-Erviti L., Seow Y., Yin H., Betts C., Lakhal S., Wood M.J. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011, 29(4):341-345. [Epub 2011/03/23].
15. Wahlgren J., De L.K.T., Brisslert M., Vaziri Sani F., Telemo E., Sunnerhagen P., et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 2012, 40(17):e130. [Epub 2012/05/24].
16. Johnsen K.B., Gudbergsson J.M., Skov M.N., Pilgaard L., Moos T., Duroux M. A comprehensive overview of exosomes as drug delivery vehicles-endogenous nanocarriers for targeted cancer therapy. Biochim Biophys Acta 2014, 1846(1):75-87. [Epub 2014/04/22].
17. Shtam T.A., Kovalev R.A., Varfolomeeva E.Y., Makarov E.M., Kil Y.V., Filatov M.V. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal 2013, 11:88. [Epub 2013/11/20].
18. Pan Q., Ramakrishnaiah V., Henry S., Fouraschen S., de Ruiter P.E., Kwekkeboom J., et al. Hepatic cell-to-cell transmission of small silencing RNA can extend the therapeutic reach of RNA interference (RNAi). Gut 2012, 61(9):1330-1339. [Epub 2011/12/27].
19. Chen L., Charrier A., Zhou Y., Chen R., Yu B., Agarwal K., et al. Epigenetic regulation of connective tissue growth factor by MicroRNA-214 delivery in exosomes from mouse or human hepatic stellate cells. Hepatology 2014, 59(3):1118-1129. [Epub 2013/10/15].
20. Maguire C.A., Balaj L., Sivaraman S., Crommentuijn M.H., Ericsson M., Mincheva-Nilsson L., et al. Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther 2012, 20(5):960-971. [Epub 2012/02/09].
21. Sun D., Zhuang X., Xiang X., Liu Y., Zhang S., Liu C., et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther 2010, 18(9):1606-1614. [Epub 2010/06/24].
22. Zhuang X., Xiang X., Grizzle W., Sun D., Zhang S., Axtell R.C., et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther 2011, 19(10):1769-1779. [Epub 2011/09/15].
23. Tian Y., Li S., Song J., Ji T., Zhu M., Anderson G.J., et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 2014, 35(7):2383-2390. [Epub 2013/12/19].
24. Thery C., Amigorena S., Raposo G., Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006, 3:26-27. [Chapter 3:Unit 3 22. Epub 2008/01/30].
25. Thery C., Ostrowski M., Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009, 9(8):581-593. [Epub 2009/06/06].
26. Wiklander O.P., Nordin J.Z., O'Loughlin A., Gustafsson Y., Corso G., Mager I., et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles 2015, 4:26316. [Epub 2015/04/23].
27. Pidaparti M., Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr Blood Cancer 2012, 59(3):436-439. [Epub 2011/10/25].
28. Batrakova E.V., Li S., Elmquist W.F., Miller D.W., Alakhov V.Y., Kabanov A.V. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 2001, 85(12):1987-1997.
29. Haney M.J., Klyachko N.L., Zhao Y., Gupta R., Plotnikova E.G., He Z., et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release 2015, 207:18-30. [Epub 2015/04/04].
30. Laulagnier K., Vincent-Schneider H., Hamdi S., Subra C., Lankar D., Record M. Characterization of exosome subpopulations from RBL-2H3 cells using fluorescent lipids. Blood Cells Mol Dis 2005, 35(2):116-121. [Epub 2005/07/19].
31. Boldytev I.A., Molotkovskii I.G. A synthesis and properties of new 4,4-difluoro-3a,4a-diaza-s-indacene (BODIPY)-labeled lipids. Bioorg Khim 2006, 32(1):87-92. [Epub 2006/03/10].
32. Batrakova E.V., Li S., Brynskikh A.M., Sharma A.K., Li Y., Boska M., et al. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J Control Release 2010, 143(3):290-301. [Epub 2010/01/16].
33. Batrakova E.V., Kelly D.L., Li S., Li Y., Yang Z., Xiao L., et al. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm 2006, 3(2):113-123. [Epub 2006/04/04].
34. Ferrari M., Fornasiero M., Isetta A. MTT colorimetric assay for testing macrophage cytotoxic activity in vitro. J Immunol Methods 1990, 131(2):165-172.
35. Sena-Esteves M., Tebbets J.C., Steffens S., Crombleholme T., Flake A.W. Optimized large-scale production of high titer lentivirus vector pseudotypes. J Virol Methods 2004, 122(2):131-139. [Epub 2004/11/16].
36. Brynskikh A.M., Zhao Y., Mosley R.L., Li S., Boska M.D., Klyachko N.L., et al. Macrophage delivery of therapeutic nanozymes in a murine model of Parkinson's disease. Nanomedicine (Lond) 2010, 5(3):379-396. [Epub 2010/04/17].
37. De Jong W.H., Borm P.J. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008, 3(2):133-149. [Epub 2008/08/09].
38. Batrakova E., Lee S., Li S., Venne A., Alakhov V., Kabanov A. Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm Res 1999, 16(9):1373-1379.
39. Batrakova E., Li S., Alakhov V., Miller D., Kabanov A. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther 2003, 304(2):845-854.
40. Batrakova E.V., Li S., Alakhov V.Y., Elmquist W.F., Miller D.W., Kabanov A.V. Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res 2003, 20(10):1581-1590.
41. Kalra H., Adda C.G., Liem M., Ang C.S., Mechler A., Simpson R.J., et al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics 2013, 13(22):3354-3364. [Epub 2013/10/12].
42. Mulcahy L.A., Pink R.C., Carter D.R. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles 2014, 3. [Epub 2014/08/22].
43. Safaei R., Larson B.J., Cheng T.C., Gibson M.A., Otani S., Naerdemann W., et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005, 4(10):1595-1604. [Epub 2005/10/18].
44. Yamagishi T., Sahni S., Sharp D.M., Arvind A., Jansson P.J., Richardson D.R. P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration. J Biol Chem 2013, 288(44):31761-31771. [Epub 2013/09/26].
45. Pascucci L., Cocce V., Bonomi A., Ami D., Ceccarelli P., Ciusani E., et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release 2014, 192:262-270. [Epub 2014/08/02].
46. Finn O.J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012, 23(Suppl. 8):viii6-viii9. [Epub 2012/08/29].
47. Parolini I., Federici C., Raggi C., Lugini L., Palleschi S., De Milito A., et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009, 284(49):34211-34222. [Epub 2009/10/06].